Protalix BioTherapeutics, Inc. (PLX)
USD 1.71
(-1.72%)
USD 1.71
(-1.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.05 Million USD | -21.94% |
| 2022 | 41.06 Million USD | -3.3% |
| 2021 | 42.46 Million USD | -13.89% |
| 2020 | 49.31 Million USD | -9.54% |
| 2019 | 54.51 Million USD | 23.21% |
| 2018 | 44.24 Million USD | 9.62% |
| 2017 | 40.36 Million USD | 18.84% |
| 2016 | 33.96 Million USD | 24.39% |
| 2015 | 27.3 Million USD | -12.8% |
| 2014 | 31.31 Million USD | -5.69% |
| 2013 | 33.2 Million USD | -13.66% |
| 2012 | 38.45 Million USD | 1.26% |
| 2011 | 37.97 Million USD | 3.11% |
| 2010 | 36.82 Million USD | 27.95% |
| 2009 | 28.78 Million USD | 19.08% |
| 2008 | 24.17 Million USD | -1.61% |
| 2007 | 24.56 Million USD | 151.43% |
| 2006 | 9.77 Million USD | 10373.23% |
| 2005 | 93.29 Thousand USD | -43.66% |
| 2004 | 165.58 Thousand USD | 12.35% |
| 2003 | 147.38 Thousand USD | -11.1% |
| 2002 | 165.79 Thousand USD | -57.03% |
| 2001 | 385.78 Thousand USD | 1.03% |
| 2000 | 381.85 Thousand USD | -77.37% |
| 1999 | 1.68 Million USD | -41.9% |
| 1998 | 2.9 Million USD | 1666.77% |
| 1997 | 164.38 Thousand USD | 273.1% |
| 1996 | 44.05 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6 Million USD | -17.16% |
| 2024 Q2 | 6.44 Million USD | 7.38% |
| 2023 Q1 | 8.96 Million USD | 2.83% |
| 2023 FY | 32.05 Million USD | -21.94% |
| 2023 Q3 | 7.33 Million USD | -13.72% |
| 2023 Q2 | 8.5 Million USD | -5.09% |
| 2023 Q4 | 7.24 Million USD | -1.28% |
| 2022 Q1 | 11.92 Million USD | 7.33% |
| 2022 Q2 | 10.19 Million USD | -14.52% |
| 2022 Q3 | 10.23 Million USD | 0.43% |
| 2022 FY | 41.06 Million USD | -3.3% |
| 2022 Q4 | 8.71 Million USD | -14.84% |
| 2021 Q2 | 10.86 Million USD | 5.85% |
| 2021 Q1 | 10.26 Million USD | -26.21% |
| 2021 Q3 | 10.23 Million USD | -5.75% |
| 2021 FY | 42.46 Million USD | -13.89% |
| 2021 Q4 | 11.1 Million USD | 8.51% |
| 2020 Q4 | 13.9 Million USD | 32.37% |
| 2020 Q1 | 13.52 Million USD | 7.28% |
| 2020 Q2 | 11.38 Million USD | -15.87% |
| 2020 Q3 | 10.5 Million USD | -7.7% |
| 2020 FY | 49.31 Million USD | -9.54% |
| 2019 Q3 | 12.58 Million USD | -18.22% |
| 2019 FY | 54.51 Million USD | 23.21% |
| 2019 Q1 | 13.92 Million USD | 5.54% |
| 2019 Q2 | 15.39 Million USD | 10.5% |
| 2019 Q4 | 12.6 Million USD | 0.17% |
| 2018 Q4 | 13.19 Million USD | 3.84% |
| 2018 Q3 | 12.7 Million USD | 35.22% |
| 2018 Q1 | 8.94 Million USD | -27.5% |
| 2018 FY | 44.24 Million USD | 9.62% |
| 2018 Q2 | 9.39 Million USD | 5.12% |
| 2017 FY | 40.36 Million USD | 18.84% |
| 2017 Q2 | 11.64 Million USD | 62.43% |
| 2017 Q4 | 12.33 Million USD | 33.69% |
| 2017 Q3 | 9.22 Million USD | -20.75% |
| 2017 Q1 | 7.16 Million USD | -19.02% |
| 2016 Q1 | 8.02 Million USD | 25.16% |
| 2016 Q3 | 7.07 Million USD | -29.48% |
| 2016 Q2 | 10.02 Million USD | 25.0% |
| 2016 FY | 33.96 Million USD | 24.39% |
| 2016 Q4 | 8.84 Million USD | 25.16% |
| 2015 Q2 | 7.04 Million USD | -6.51% |
| 2015 FY | 27.3 Million USD | -12.8% |
| 2015 Q4 | 6.4 Million USD | 1.6% |
| 2015 Q3 | 6.3 Million USD | -10.53% |
| 2015 Q1 | 7.54 Million USD | 9.47% |
| 2014 FY | 31.31 Million USD | -5.69% |
| 2014 Q4 | 6.88 Million USD | -15.14% |
| 2014 Q1 | 9.77 Million USD | 0.62% |
| 2014 Q3 | 8.11 Million USD | 24.34% |
| 2014 Q2 | 6.52 Million USD | -33.24% |
| 2013 Q1 | 7.42 Million USD | -17.83% |
| 2013 Q3 | 7.41 Million USD | -14.16% |
| 2013 FY | 33.2 Million USD | -13.66% |
| 2013 Q4 | 9.71 Million USD | 31.02% |
| 2013 Q2 | 8.64 Million USD | 16.35% |
| 2012 FY | 38.45 Million USD | 1.26% |
| 2012 Q4 | 9.03 Million USD | 5.29% |
| 2012 Q3 | 8.58 Million USD | -30.55% |
| 2012 Q1 | 8.47 Million USD | -7.42% |
| 2012 Q2 | 12.35 Million USD | 45.86% |
| 2011 Q3 | 9.44 Million USD | 3.58% |
| 2011 Q2 | 9.11 Million USD | -11.13% |
| 2011 Q1 | 10.26 Million USD | -15.42% |
| 2011 Q4 | 9.15 Million USD | -3.09% |
| 2011 FY | 37.97 Million USD | 3.11% |
| 2010 Q2 | 11.29 Million USD | 21.92% |
| 2010 Q3 | 4.96 Million USD | -56.01% |
| 2010 FY | 36.82 Million USD | 27.95% |
| 2010 Q4 | 12.13 Million USD | 144.21% |
| 2010 Q1 | 9.26 Million USD | -21.7% |
| 2009 Q4 | 11.82 Million USD | 95.63% |
| 2009 Q3 | 6.04 Million USD | 2.95% |
| 2009 Q2 | 5.87 Million USD | 16.64% |
| 2009 FY | 28.78 Million USD | 19.08% |
| 2009 Q1 | 5.03 Million USD | -19.98% |
| 2008 Q2 | 4.89 Million USD | -21.79% |
| 2008 FY | 24.17 Million USD | -1.61% |
| 2008 Q4 | 6.29 Million USD | -6.34% |
| 2008 Q1 | 6.26 Million USD | 4.04% |
| 2008 Q3 | 6.71 Million USD | 37.16% |
| 2007 Q2 | 13.11 Million USD | 246.89% |
| 2007 FY | 24.56 Million USD | 151.43% |
| 2007 Q4 | 6.02 Million USD | -6.39% |
| 2007 Q3 | 6.43 Million USD | -50.97% |
| 2007 Q1 | 3.78 Million USD | -60.64% |
| 2006 Q2 | 26.11 Thousand USD | 23.69% |
| 2006 Q1 | 21.11 Thousand USD | -19.12% |
| 2006 FY | 9.77 Million USD | 10373.23% |
| 2006 Q4 | 9.6 Million USD | 8067.11% |
| 2006 Q3 | 117.62 Thousand USD | 350.44% |
| 2005 FY | 93.29 Thousand USD | -43.66% |
| 2005 Q4 | 26.1 Thousand USD | -27.26% |
| 2005 Q3 | 35.88 Thousand USD | 75.52% |
| 2005 Q2 | 20.44 Thousand USD | 88.21% |
| 2005 Q1 | 10.86 Thousand USD | -66.17% |
| 2004 Q3 | 43.88 Thousand USD | -26.75% |
| 2004 Q1 | 29.68 Thousand USD | -39.24% |
| 2004 Q2 | 59.9 Thousand USD | 101.82% |
| 2004 Q4 | 32.1 Thousand USD | -26.83% |
| 2004 FY | 165.58 Thousand USD | 12.35% |
| 2003 Q1 | 34.55 Thousand USD | -34.23% |
| 2003 FY | 147.38 Thousand USD | -11.1% |
| 2003 Q2 | 30.96 Thousand USD | -10.39% |
| 2003 Q3 | 33.01 Thousand USD | 6.64% |
| 2003 Q4 | 48.85 Thousand USD | 47.96% |
| 2002 Q1 | 40.62 Thousand USD | -74.0% |
| 2002 Q2 | 36.87 Thousand USD | -9.23% |
| 2002 Q4 | 52.53 Thousand USD | 46.9% |
| 2002 Q3 | 35.76 Thousand USD | -3.02% |
| 2002 FY | 165.79 Thousand USD | -57.03% |
| 2001 Q3 | 58.67 Thousand USD | -9.8% |
| 2001 FY | 385.78 Thousand USD | 1.03% |
| 2001 Q2 | 65.04 Thousand USD | -38.53% |
| 2001 Q1 | 105.82 Thousand USD | -51.96% |
| 2001 Q4 | 156.24 Thousand USD | 166.3% |
| 2000 Q3 | 15.57 Thousand USD | -79.98% |
| 2000 FY | 381.85 Thousand USD | -77.37% |
| 2000 Q1 | 68.18 Thousand USD | -57.64% |
| 2000 Q4 | 220.29 Thousand USD | 1314.58% |
| 2000 Q2 | 77.8 Thousand USD | 14.12% |
| 1999 Q2 | 464.11 Thousand USD | -25.68% |
| 1999 Q1 | 624.48 Thousand USD | -77.62% |
| 1999 FY | 1.68 Million USD | -41.9% |
| 1999 Q4 | 160.96 Thousand USD | -63.23% |
| 1999 Q3 | 437.8 Thousand USD | -5.67% |
| 1998 Q1 | 190 Thousand USD | 0.0% |
| 1998 Q2 | 1.5 Million USD | 689.47% |
| 1998 Q3 | 1.87 Million USD | 24.67% |
| 1998 Q4 | 2.79 Million USD | 49.2% |
| 1998 FY | 2.9 Million USD | 1666.77% |
| 1997 Q2 | 140 Thousand USD | 40.0% |
| 1997 Q3 | 200 Thousand USD | 42.86% |
| 1997 Q4 | 190 Thousand USD | -5.0% |
| 1997 FY | 164.38 Thousand USD | 273.1% |
| 1997 Q1 | 100 Thousand USD | 400.0% |
| 1996 FY | 44.05 Thousand USD | 0.0% |
| 1996 Q3 | 10 Thousand USD | 0.0% |
| 1996 Q4 | 20 Thousand USD | 100.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 0.075% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -245.835% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -175.148% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 38.363% |
| Azitra, Inc. | 8.3 Million USD | -286.057% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -258.604% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -367.075% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | -10.555% |
| CEL-SCI Corporation | 31.47 Million USD | -1.83% |
| iBio, Inc. | 16.85 Million USD | -90.118% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 2.893% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -58.812% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -28.92% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -130.067% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -148.504% |
| NanoViricides, Inc. | 8.51 Million USD | -276.369% |
| Oragenics, Inc. | 5.45 Million USD | -487.9% |
| BiomX Inc. | 26.81 Million USD | -19.535% |
| BiomX Inc. | 26.81 Million USD | -19.535% |
| Palatin Technologies, Inc. | 34.67 Million USD | 7.552% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 19.499% |